---
url: "https://dfylegitscript.com/research/glp-1-compounding-warning-letters"
title: "FDA warning letters on compounded GLP-1 marketing"
description: "110 FDA warning letters issued to telehealth and compounding companies over compounded GLP-1 marketing, in 3 enforcement rounds, each row linked to the letter on fda.gov."
modified: "2026-06-08T00:00:00+00:00"
---

# FDA warning letters on compounded GLP-1 marketing

110 FDA warning letters issued to telehealth and compounding companies over compounded GLP-1 marketing, in 3 enforcement rounds, each row linked to the letter on fda.gov.

## Key takeaways

- The FDA has issued 110 warning letters to telehealth and compounding companies over compounded GLP-1 marketing, across 3 enforcement rounds.
- Every one of the 110 letters cites misbranding, and 96 cite claims that implied a compounded drug was FDA-approved or equivalent to the brand-name product.
- Compounded semaglutide and tirzepatide are not FDA-approved drugs, and no compounded drug may be marketed as though it had been.
- A warning letter is a marketing and advertising finding. It is a direct problem for LegitScript certification, which reviews the claims your website makes.
- The letters are dated up to eight days before the FDA publishes them, so press coverage and the letters themselves often carry different dates.

## Letters by enforcement round

| Letters dated | Letters issued |
| --- | --- |
| 8 June 2026 | 25 |
| 20 February 2026 | 30 |
| 9 September 2025 | 55 |

## Cited violations

A letter usually cites several, so these sum to more than the letter count.

| Cited violation | Letters citing it |
| --- | --- |
| Misbranding | 110 |
| Implied the compounded drug is FDA-approved or equivalent to the brand | 96 |
| Misleading comparison to an approved product | 75 |
| Other cited violation | 53 |
| Unsupported safety or efficacy claim | 53 |
| Unapproved new drug | 6 |
| Unsupported "personalized dosing" claim | 2 |

## Every letter

| Company | Letter date | FDA reference | Products named | Cited violations | Source |
| --- | --- | --- | --- | --- | --- |
| Altru Telehealth, LLC dba Altru Telehealth | 2026-06-08 | 728274 | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product; Other cited violation; Unsupported safety or efficacy claim | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/altru-telehealth-llc-dba-altru-telehealth-728274-06082026 |
| Amie Health, Inc. dba Amie | 2026-06-08 | 728276 | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product; Other cited violation; Unsupported safety or efficacy claim | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/amie-health-inc-dba-amie-728276-06082026 |
| Clover Meds LLC dba Clover Meds | 2026-06-08 | 728234 | semaglutide, tirzepatide | Misbranding; Other cited violation | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/clover-meds-llc-dba-clover-meds-728234-06082026 |
| D&H Medical Services | 2026-06-08 | 728238 | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product; Unsupported safety or efficacy claim | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/dh-medical-services-728238-06082026 |
| Eden Health International Inc. dba Eden | 2026-06-08 | 728279 | semaglutide, tirzepatide | Misbranding; Other cited violation | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/eden-health-international-inc-dba-eden-728279-06082026 |
| Ezra Holdco LLC dba Ezra | 2026-06-08 | 730995 | semaglutide, tirzepatide | Misbranding; Other cited violation | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ezra-holdco-llc-dba-ezra-730995-06082026 |
| FITISH | 2026-06-08 | 728280 | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product; Other cited violation; Unsupported safety or efficacy claim | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fitish-728280-06082026 |
| FitRX, LLC dba AM RX | 2026-06-08 | 728275 | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product; Other cited violation; Unsupported safety or efficacy claim | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fitrx-llc-dba-am-rx-728275-06082026 |
| Glow Medispa, LLC dba Mint Med | 2026-06-08 | 730390 | semaglutide, tirzepatide | Misbranding; Other cited violation | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/glow-medispa-llc-dba-mint-med-730390-06082026 |
| HydraMed IV LLC dba HydraMed | 2026-06-08 | 728282 | semaglutide, tirzepatide | Misbranding; Other cited violation | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/hydramed-iv-llc-dba-hydramed-728282-06082026 |
| Joi and Blokes dba Joi + Blokes | 2026-06-08 | 728283 | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product; Other cited violation; Unsupported safety or efficacy claim | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/joi-and-blokes-dba-joi-blokes-728283-06082026 |
| Maximus Health, Inc. dba Maximus | 2026-06-08 | 730095 | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Other cited violation; Unsupported safety or efficacy claim | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/maximus-health-inc-dba-maximus-730095-06082026 |
| Medica Weight Loss | 2026-06-08 | 728284 | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Other cited violation; Unsupported safety or efficacy claim | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/medica-weight-loss-728284-06082026 |
| Momentum Health 360 dba Momentum Health | 2026-06-08 | 728286 | liraglutide, semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product; Other cited violation; Unsupported safety or efficacy claim | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/momentum-health-360-dba-momentum-health-728286-06082026 |
| NativeMed LLC dba NativeMed | 2026-06-08 | 728287 | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product; Other cited violation; Unsupported safety or efficacy claim | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nativemed-llc-dba-nativemed-728287-06082026 |
| Nexlife Inc. dba Nexlife | 2026-06-08 | 730096 | semaglutide, tirzepatide | Misbranding; Other cited violation | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nexlife-inc-dba-nexlife-730096-06082026 |
| Nexus Health Solutions LLC dba Harper Meds | 2026-06-08 | 728281 | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product; Other cited violation; Unsupported safety or efficacy claim | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nexus-health-solutions-llc-dba-harper-meds-728281-06082026 |
| Nova Vascular LLC dba NOVARX | 2026-06-08 | 728290 | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product; Other cited violation; Unsupported safety or efficacy claim | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nova-vascular-llc-dba-novarx-728290-06082026 |
| OrderlyMeds LLC dba OrderlyMeds | 2026-06-08 | 728291 | semaglutide, tirzepatide | Misbranding; Other cited violation | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/orderlymeds-llc-dba-orderlymeds-728291-06082026 |
| Public Health Solution LLC dba DrMedHealth | 2026-06-08 | 728278 | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product; Unsupported safety or efficacy claim | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/public-health-solution-llc-dba-drmedhealth-728278-06082026 |
| Ready Med | 2026-06-08 | 730317 | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product; Other cited violation; Unsupported safety or efficacy claim | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ready-med-730317-06082026 |
| Roen Health, Inc. dba RoenRx | 2026-06-08 | 728293 | semaglutide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product; Other cited violation; Unsupported safety or efficacy claim | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/roen-health-inc-dba-roenrx-728293-06082026 |
| Thrivelab Co. dba Thrivelab | 2026-06-08 | 728294 | semaglutide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product; Other cited violation; Unsupported safety or efficacy claim | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/thrivelab-co-dba-thrivelab-728294-06082026 |
| Trinity HealthCare Supply, LLC dba altRx | 2026-06-08 | 728236 | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Other cited violation; Unsupported safety or efficacy claim | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/trinity-healthcare-supply-llc-dba-altrx-728236-06082026 |
| VivioMD Group LLC dba VivioMD | 2026-06-08 | 728295 | semaglutide, tirzepatide | Misbranding; Other cited violation | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/viviomd-group-llc-dba-viviomd-728295-06082026 |
| 24HrDoc, Inc. dba 24HrDoc | 2026-02-20 | 717984 | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product; Other cited violation; Unsupported safety or efficacy claim | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/24hrdoc-inc-dba-24hrdoc-717984-02202026 |
| Alan Health Technologies Inc. dba Alan | 2026-02-20 | 721814 | semaglutide, tirzepatide | Misbranding; Other cited violation | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/alan-health-technologies-inc-dba-alan-721814-02202026 |
| Aspen Aesthetics dba Fifty 410 | 2026-02-20 | 721481 | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Other cited violation; Unsupported safety or efficacy claim | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/aspen-aesthetics-dba-fifty-410-721481-02202026 |
| Belle Health LLC dba Belle | 2026-02-20 | 721795 | semaglutide, tirzepatide | Misbranding; Other cited violation | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/belle-health-llc-dba-belle-721795-02202026 |
| Better Health Labs, Inc. dba Measured | 2026-02-20 | 721454 | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product; Other cited violation; Unsupported safety or efficacy claim | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/better-health-labs-inc-dba-measured-721454-02202026 |
| Bliv Wellness LLC dba Bliv | 2026-02-20 | 721479 | semaglutide, tirzepatide | Misbranding; Other cited violation | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/bliv-wellness-llc-dba-bliv-721479-02202026 |
| BluefitMD | 2026-02-20 | 721446 | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product; Other cited violation; Unsupported safety or efficacy claim | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/bluefitmd-721446-02202026 |
| Deluxe IV Aesthetics PLLC dba Deluxe IV and Aesthetics | 2026-02-20 | 721447 | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product; Other cited violation; Unsupported safety or efficacy claim | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/deluxe-iv-aesthetics-pllc-dba-deluxe-iv-and-aesthetics-721447-02202026 |
| Dripgym Mobile Parent, LLC dba Amp Health | 2026-02-20 | 717992 | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product; Other cited violation; Unsupported safety or efficacy claim | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/dripgym-mobile-parent-llc-dba-amp-health-717992-02202026 |
| FitRX, LLC dba FitRx | 2026-02-20 | 717987 | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product; Other cited violation; Unsupported safety or efficacy claim | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fitrx-llc-dba-fitrx-717987-02202026 |
| Genesis Health International Inc. dba Genesis | 2026-02-20 | 721451 | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product; Other cited violation; Unsupported safety or efficacy claim | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/genesis-health-international-inc-dba-genesis-721451-02202026 |
| Good Girl LLC dba GoodGirlRX | 2026-02-20 | 721449 | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Other cited violation; Unsupported safety or efficacy claim | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/good-girl-llc-dba-goodgirlrx-721449-02202026 |
| Ivim Services LLC dba Ivim | 2026-02-20 | 721816 | semaglutide, tirzepatide | Misbranding; Other cited violation | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ivim-services-llc-dba-ivim-721816-02202026 |
| Join Josie | 2026-02-20 | 717986 | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product; Other cited violation; Unsupported safety or efficacy claim | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/join-josie-717986-02202026 |
| Kare Solutions, LLC dba Zappy | 2026-02-20 | 717991 | liraglutide, semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product; Other cited violation; Unsupported safety or efficacy claim | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/kare-solutions-llc-dba-zappy-717991-02202026 |
| Kin Meds | 2026-02-20 | 721450 | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Other cited violation; Unsupported safety or efficacy claim | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/kin-meds-721450-02202026 |
| Lean Rx, Inc. dba SkinnyRx | 2026-02-20 | 717989 | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product; Other cited violation; Unsupported safety or efficacy claim | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lean-rx-inc-dba-skinnyrx-717989-02202026 |
| Levity Inc. dba Levity | 2026-02-20 | 717990 | liraglutide, semaglutide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product; Other cited violation; Unsupported safety or efficacy claim | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/levity-inc-dba-levity-717990-02202026 |
| MEDVi, LLC dba MEDVi | 2026-02-20 | 721455 | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product; Other cited violation; Unsupported safety or efficacy claim | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/medvi-llc-dba-medvi-721455-02202026 |
| MaxLife Technologies Inc. dba Maxlife | 2026-02-20 | 721453 | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product; Other cited violation; Unsupported safety or efficacy claim | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/maxlife-technologies-inc-dba-maxlife-721453-02202026 |
| NewSelf Limited dba NewSelf | 2026-02-20 | 721472 | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product; Other cited violation; Unsupported safety or efficacy claim | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/newself-limited-dba-newself-721472-02202026 |
| Newman Clinic, PLLC dba Newman Clinic | 2026-02-20 | 721470 | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product; Other cited violation; Unsupported safety or efficacy claim | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/newman-clinic-pllc-dba-newman-clinic-721470-02202026 |
| Peaks Curative, LLC dba Peaks | 2026-02-20 | 721817 | semaglutide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Other cited violation; Unsupported safety or efficacy claim | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peaks-curative-llc-dba-peaks-721817-02202026 |
| PharmaZee | 2026-02-20 | 721473 | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product; Other cited violation; Unsupported safety or efficacy claim | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pharmazee-721473-02202026 |
| Premium Health Management Inc. dba Premium Health | 2026-02-20 | 721474 | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product; Other cited violation; Unsupported safety or efficacy claim | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/premium-health-management-inc-dba-premium-health-721474-02202026 |
| Refills Health, LLC dba Refills Health | 2026-02-20 | 721475 | semaglutide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Other cited violation; Unsupported safety or efficacy claim | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/refills-health-llc-dba-refills-health-721475-02202026 |
| Strut Health, LLC dba Strut | 2026-02-20 | 721448 | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product; Other cited violation; Unsupported safety or efficacy claim | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/strut-health-llc-dba-strut-721448-02202026 |
| Viv Health, Inc. dba VIV RX | 2026-02-20 | 721818 | semaglutide, tirzepatide | Misbranding; Other cited violation | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/viv-health-inc-dba-viv-rx-721818-02202026 |
| Weightless Medical LLC dba WeightCare | 2026-02-20 | 721478 | semaglutide, tirzepatide | Misbranding; Other cited violation | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/weightless-medical-llc-dba-weightcare-721478-02202026 |
| Zeuss LLC dba Zeuss | 2026-02-20 | 717985 | tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Other cited violation; Unsupported safety or efficacy claim | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/zeuss-llc-dba-zeuss-717985-02202026 |
| ASN-LABS | 2025-09-09 | 716459 | retatrutide, semaglutide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product; Unapproved new drug | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/asn-labs-716459-09092025 |
| All American Wellness | 2025-09-09 | 715991 | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/all-american-wellness-715991-09092025 |
| Amazing Meds | 2025-09-09 | 715506 | retatrutide, semaglutide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product; Unapproved new drug | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/amazing-meds-715506-09092025 |
| Bioverse, Inc. dba Bioverse | 2025-09-09 | 716508 | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/bioverse-inc-dba-bioverse-716508-09092025 |
| Body Good Studio | 2025-09-09 | 716460 | semaglutide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/body-good-studio-716460-09092025 |
| Canada Med Stop | 2025-09-09 | 716517 | semaglutide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/canada-med-stop-716517-09092025 |
| Cosmo Medical Spa dba Cosmo Med Spa | 2025-09-09 | 715873 | semaglutide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/cosmo-medical-spa-dba-cosmo-med-spa-715873-09092025 |
| Curex | 2025-09-09 | 716821 | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product; Unsupported safety or efficacy claim | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/curex-716821-09092025 |
| Dr. Gater’s Weight Loss & Wellness | 2025-09-09 | 712866 | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/dr-gaters-weight-loss-wellness-712866-09092025 |
| EA WORKS Limited Liability Company dba Trust Labs | 2025-09-09 | 715798 | retatrutide, semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Unapproved new drug | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ea-works-limited-liability-company-dba-trust-labs-715798-09092025 |
| Elevate Your Wellness LLC, dba Elevated | 2025-09-09 | 719811 | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Unsupported "personalized dosing" claim | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/elevate-your-wellness-llc-dba-elevated-719811-09092025 |
| Elite Health Center | 2025-09-09 | 715869 | semaglutide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/elite-health-center-715869-09092025 |
| EvoLife Wellness | 2025-09-09 | 715507 | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Unsupported safety or efficacy claim | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/evolife-wellness-715507-09092025 |
| Expert Aesthetics | 2025-09-09 | 715796 | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/expert-aesthetics-715796-09092025 |
| FWD Care, Inc. dba FWD | 2025-09-09 | 716696 | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fwd-care-inc-dba-fwd-716696-09092025 |
| Fancy Meds, LLC dba Fancy Meds | 2025-09-09 | 716487 | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fancy-meds-llc-dba-fancy-meds-716487-09092025 |
| FitRX, LLC dba Zealthy | 2025-09-09 | 716501 | semaglutide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fitrx-llc-dba-zealthy-716501-09092025 |
| GLP-1 Solution | 2025-09-09 | 715883 | retatrutide, semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product; Unapproved new drug | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/glp-1-solution-715883-09092025 |
| GenLabMeds | 2025-09-09 | 713650 | retatrutide, semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product; Unapproved new drug | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/genlabmeds-713650-09092025 |
| Get.Fit.Medical, LLC dba Get.Fit.Medical | 2025-09-09 | 715801 | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/getfitmedical-llc-dba-getfitmedical-715801-09092025 |
| HealBerry | 2025-09-09 | 719809 | semaglutide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/healberry-719809-09092025 |
| Healthon Inc. dba Healthon | 2025-09-09 | 719809 | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product; Unsupported safety or efficacy claim | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/healthon-inc-dba-healthon-719809-09092025 |
| Healthy Living Clinic | 2025-09-09 |  | semaglutide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/healthy-living-clinic-09092025 |
| Healthy Male | 2025-09-09 | 716506 | tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Unsupported safety or efficacy claim | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/healthy-male-716506-09092025 |
| Hims & Hers Health, Inc. dba Hers | 2025-09-09 | 716825 | semaglutide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product; Unsupported safety or efficacy claim | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/hims-hers-health-inc-dba-hers-716825-09092025 |
| Hims & Hers Health, Inc. dba Hims | 2025-09-09 | 716567 | semaglutide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product; Unsupported safety or efficacy claim | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/hims-hers-health-inc-dba-hims-716567-09092025 |
| Intimate Rose | 2025-09-09 | 716458 | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/intimate-rose-716458-09092025 |
| Invigorate Med Spa | 2025-09-09 | 715872 | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/invigorate-med-spa-715872-09092025 |
| JulyMD | 2025-09-09 | 716828 | semaglutide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/julymd-716828-09092025 |
| Las Villas Health Care LLC dba Villas Health | 2025-09-09 | 716504 | semaglutide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product; Unsupported safety or efficacy claim | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/las-villas-health-care-llc-dba-villas-health-716504-09092025 |
| Lean Dreams LLC dba LeanDreams | 2025-09-09 | 716697 | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lean-dreams-llc-dba-leandreams-716697-09092025 |
| Lovely Meds, Inc. dba Lovely Meds | 2025-09-09 | 716829 | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lovely-meds-inc-dba-lovely-meds-716829-09092025 |
| Lumimeds | 2025-09-09 | 716510 | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lumimeds-716510-09092025 |
| Lyfe Rx | 2025-09-09 |  | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Unsupported safety or efficacy claim | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lyfe-rx-09092025 |
| Mane & Steel, LLC. dba Mane & Steel | 2025-09-09 | 716455 | semaglutide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Unsupported safety or efficacy claim | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/mane-steel-llc-dba-mane-steel-716455-09092025 |
| Master Pharmaceuticals Group | 2025-09-09 | 715800 | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/master-pharmaceuticals-group-715800-09092025 |
| Matthew Stern, CEO MyStart Health LLC. | 2025-09-09 | 714755 | semaglutide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/matthew-stern-ceo-mystart-health-llc-714755-09092025 |
| MedClub by Dr. Jenn | 2025-09-09 | 712126 | retatrutide, semaglutide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product; Unapproved new drug | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/medclub-dr-jenn-712126-09092025 |
| Nuvo Life Health Inc. dba Nuvo Life Health | 2025-09-09 | 715794 | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nuvo-life-health-inc-dba-nuvo-life-health-715794-09092025 |
| Remedy Meds | 2025-09-09 | 716830 | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/remedy-meds-716830-09092025 |
| Reset IV, LLC dba Reset IV | 2025-09-09 | 716488 | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/reset-iv-llc-dba-reset-iv-716488-09092025 |
| SemaBio | 2025-09-09 | 715866 | semaglutide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/semabio-715866-09092025 |
| SimpleRx | 2025-09-09 | 715874 | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/simplerx-715874-09092025 |
| Slendid | 2025-09-09 | 716700 | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Unsupported safety or efficacy claim | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/slendid-716700-09092025 |
| Sprout Health Partners LLC dba Sprout Health | 2025-09-09 | 715879 | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/sprout-health-partners-llc-dba-sprout-health-715879-09092025 |
| TRYM Health, Inc. dba TRYM Health | 2025-09-09 | 716699 | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product; Unsupported safety or efficacy claim | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/trym-health-inc-dba-trym-health-716699-09092025 |
| The HCG Institute | 2025-09-09 | 716512 | semaglutide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product; Unsupported safety or efficacy claim | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/hcg-institute-716512-09092025 |
| Try Nova | 2025-09-09 | 716695 | semaglutide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/try-nova-716695-09092025 |
| Tuyo Health, Inc. dba Tuyo Health | 2025-09-09 | 716502 | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tuyo-health-inc-dba-tuyo-health-716502-09092025 |
| Vitals RX | 2025-09-09 | 715868 | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/vitals-rx-715868-09092025 |
| directmeds.com, Inc. dba DirectMeds | 2025-09-09 | 716822 | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product; Unsupported "personalized dosing" claim | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/directmedscom-inc-dba-directmeds-716822-09092025 |
| eDrugstore | 2025-09-09 | 716505 | tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/edrugstore-716505-09092025 |
| iVisitDoc, Inc. dba iVisitDoc | 2025-09-09 | 716826 | semaglutide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ivisitdoc-inc-dba-ivisitdoc-716826-09092025 |
| inspire.clinic | 2025-09-09 | 715799 | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/inspireclinic-715799-09092025 |
| ybycmeds | 2025-09-09 | 715878 | semaglutide, tirzepatide | Implied the compounded drug is FDA-approved or equivalent to the brand; Misbranding; Misleading comparison to an approved product | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ybycmeds-715878-09092025 |

## Downloads

- CSV: https://dfylegitscript.com/data/glp-1-warning-letters.csv
- JSON: https://dfylegitscript.com/data/glp-1-warning-letters.json
- Licence: CC BY 4.0, https://creativecommons.org/licenses/by/4.0/

## Disclaimer

LegitScript is a trademark of LegitScript LLC. VeriScripts is an independent application-preparation service. It is not affiliated with, endorsed by, or certified by LegitScript LLC, and claims no sponsorship or partnership with it. We prepare, submit, and manage the application; LegitScript alone decides whether certification is granted. "LegitScript" is used here only to name the certification these applications are for.